首页> 外文OA文献 >Multitarget ligands and theranostics: Sharpening the medicinal chemistry sword against prion diseases
【2h】

Multitarget ligands and theranostics: Sharpening the medicinal chemistry sword against prion diseases

机译:多靶标配体和治疗学:对抗against病毒疾病的药物化学剑

摘要

Prion diseases (PrDs) are fatal neurodegenerative disorders, for which no effective therapeutic and diagnostic tools exist. The main pathogenic event has been identified as the misfolding of a disease-associated prion protein. Nevertheless, pathogenesis seems to involve an intricate array of concomitant processes. Thus, it may be unlikely that drugs acting on single targets can effectively control PrDs. In addition, diagnosis occurs late in the disease process, by which point it is difficult to determine a successful therapeutic intervention. In this context, multitarget ligands (MTLs) and theranostic ligands (TLs) emerge for their potential to effectively cure and diagnose PrDs. In this review, we discuss the medicinal chemistry challenges of identifying novel MTLs and TLs against PrDs, and envision their impact on prion drug discovery. © 2014 Future Science Ltd.
机译:on病毒病(PrDs)是致命的神经退行性疾病,目前尚无有效的治疗和诊断工具。主要的致病事件已被确定为与疾病相关的病毒蛋白的错误折叠。然而,发病机制似乎涉及一系列复杂的伴随过程。因此,作用于单一靶标的药物不可能有效地控制PrDs。另外,诊断发生在疾病过程的后期,因此很难确定成功的治疗干预措施。在这种情况下,多靶点配体(MTL)和治疗诊断性配体(TL)因其有效治愈和诊断PrDs的潜力而出现。在这篇综述中,我们讨论了识别针对PrDs的新型MTL和TL的药物化学挑战,并设想了它们对病毒药物发现的影响。 ©2014未来科学有限公司。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号